×
Zevra Therapeutics Long Term Debt 2014-2024 | ZVRA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Zevra Therapeutics long term debt from 2014 to 2024. Long term debt can be defined as the sum of all long term debt fields.
View More
Zevra Therapeutics Long Term Debt 2014-2024 | ZVRA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Zevra Therapeutics long term debt from 2014 to 2024. Long term debt can be defined as the sum of all long term debt fields.
Related Stocks
Company Name
Market
Cap
Zoetis (ZTS)
$79.8B
Takeda Pharmaceutical (TAK)
$43.8B
Merck (MKKGY)
$21B
Astellas Pharma (ALPMY)
$20.2B
Sandoz Group AG (SDZNY)
$19.8B
United Therapeutics (UTHR)
$18.3B
Summit Therapeutics (SMMT)
$15.8B
Neurocrine Biosciences (NBIX)
$12.7B
Shionogi (SGIOY)
$12.5B
Catalent (CTLT)
$10.8B
Madrigal Pharmaceuticals (MDGL)
$7.6B
Jazz Pharmaceuticals (JAZZ)
$7.6B
Orion OYJ (ORINY)
$6.8B
Corcept Therapeutics (CORT)
$6.2B
Ionis Pharmaceuticals (IONS)
$6.2B
Crinetics Pharmaceuticals (CRNX)
$4.9B
PTC Therapeutics (PTCT)
$3.4B
Dyne Therapeutics (DYN)
$2.9B
Catalyst Pharmaceuticals (CPRX)
$2.9B
Arrowhead Pharmaceuticals (ARWR)
$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.7B
Soleno Therapeutics (SLNO)
$2.5B
NewAmsterdam Pharma (NAMS)
$2.2B
Recursion Pharmaceuticals (RXRX)
$2B
Centessa Pharmaceuticals (CNTA)
$1.9B
Harrow (HROW)
$1.9B
Ocular Therapeutix (OCUL)
$1.7B
Xencor (XNCR)
$1.7B
ARS Pharmaceuticals (SPRY)
$1.7B
BioCryst Pharmaceuticals (BCRX)
$1.6B